Merge eClinical believes the Study ConnectApp enables the mobile management of randomization, inventory management and unblinding in clinical trials.
Study Connect, a new mobile app from Merge eClinical, allows eClinicalOS (eCOS) users to perform a wide array of clinical trial management functions from their iOS-based mobile devices.
Seamlessly integrated with eCOS, Study Connect enables researchers to:
— Manage randomization of subjects
— Coordinate dispensing and inventory management
— Unblind individual subjects, as circumstances warrant
— Stay connected with real-time customized notifications
— Monitor enrollment and establish milestone alerts
— Share top-level statistics for each study with key stakeholders using the study dashboard
— Expedite approval response times for critical study decisions such as patient study eligibility
— Maintain security with the ability to set customized role-based permissions for individual studies.
According to Zaher El-Assi, president of Merge eClinical, while there are a handful of mobile clinical research apps on the market, nearly all are limited solely to patient-reporting functions.
Mr. El-Assi also noted that in many less-developed countries cellular networks are often more reliable than electricity, meaning that vital study functions need not cease when power grids fail.
Study Connect is available in the App Store and can be reached through this link. Designed to work on both the iPad and iPhone, Study Connect can be integrated into existing trials through the Clinical Configurator, the company’s exclusive online tool for the planning and budgeting of studies on the eCOS platform.
Merge
merge.com
